Bio-Techne Collaborates to Advance Treg Therapy with $300,000 G-Rex Grant for Sonoma Bio

Bio-Techne Partners in Innovative Grant to Accelerate Treg Therapy Development

On November 3, 2025, Bio-Techne Corporation plays a pivotal role in the advancement of gene-modified regulatory T cell (Treg) therapies through a partnership with ScaleReady, Wilson Wolf Manufacturing, and CellReady. The collaboration announces that Sonoma Biotherapeutics has been awarded a $300,000 G-Rex® Grant aimed at enhancing the manufacturing process of Treg therapies. This initiative focuses on transitioning from traditional open flask methods to a more efficient and commercially viable G-Rex® platform, which is crucial for SonomaBio’s efforts to prepare for clinical trials targeting various autoimmune disorders.

John Wilson, CEO of Wilson Wolf and co-inventor of the G-Rex technology, underscores the significance of this grant in modernizing SonomaBio's production capabilities. The financial support enables SonomaBio to implement advanced optimization strategies within its Treg platform. With the integration of closed system G-Rex devices and ProPak™ GMP Cytokines, the partnership aims to establish a scalable and modular manufacturing approach. This shift not only enhances productivity but also positions SonomaBio at the forefront of Treg therapy development, essential for addressing critical patient needs in autoimmune conditions.

The G-Rex Grant Program, spearheaded by ScaleReady, has now surpassed $40 million in no-cost product commitments to bolster cell and gene-modified cell therapy (CGT) development. With grants up to $300,000, recipients gain exclusive access to a consortium of partners covering crucial areas such as cGMP manufacturing and regulatory affairs. In addition, ScaleReady introduces the LEAN Cell & Gene™ program, in collaboration with Hanson Wade, designed to improve efficiency and quality in CGT manufacturing through a series of complimentary events aimed at industry stakeholders.

In summary, the collaboration among Bio-Techne, ScaleReady, and other partners marks a significant step forward in the field of Treg therapies. The G-Rex Grant not only provides essential funding but also enables access to innovative technologies that can transform the landscape of autoimmune disorder treatments. The ongoing commitment to advancing CGT manufacturing processes signals a growing recognition of the importance of innovation in the biopharmaceutical industry. Interested parties can reach out to ScaleReady for more information about the G-Rex Grant Program and the LEAN Cell & Gene™ series.